메뉴 건너뛰기




Volumn 101, Issue 3, 2009, Pages 387-389

Societal preference values for advanced melanoma health states in the United Kingdom and Australia

Author keywords

Melanoma; Preferences; Standard gamble; Utility

Indexed keywords

ALPHA INTERFERON; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; IPILIMUMAB; TEMOZOLOMIDE;

EID: 68149158282     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605187     Document Type: Article
Times cited : (64)

References (23)
  • 1
    • 69249184799 scopus 로고    scopus 로고
    • Australian Bureau of Statistics (2007a) 2006 Census Table. http://www.abs.gov.au/
    • (2007) 2006 Census Table
  • 2
    • 68149100184 scopus 로고    scopus 로고
    • Australian Bureau of Statistics (2007b) 2006 QuickStats Australia. http://www.censusdata.abs.gov.au/ABSNavigation/prenav/ViewData?subaction= -1&producttype=QuickStats&areacode=0&action=401&collection= Census&textversion=false&breadcrumb=PL&period=2006&javascript= true&navmapdisplayed=true&
    • Australian Bureau of Statistics (2007b) 2006 QuickStats Australia. http://www.censusdata.abs.gov.au/ABSNavigation/prenav/ViewData?subaction= -1&producttype=QuickStats&areacode=0&action=401&collection= Census&textversion=false&breadcrumb=PL&period=2006&javascript= true&navmapdisplayed=true&
  • 3
    • 68149173077 scopus 로고    scopus 로고
    • Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. Cancer Therapy Evaluation Program. 9-8-2006
    • Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. Cancer Therapy Evaluation Program. 9-8-2006
  • 4
    • 0035873327 scopus 로고    scopus 로고
    • The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial
    • Cohen L, de MC, Amato RJ (2001) The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial. Cancer 91: 1949-1955
    • (2001) Cancer , vol.91 , pp. 1949-1955
    • Cohen, L.D.M.1    Amato, R.J.2
  • 5
    • 3242660084 scopus 로고    scopus 로고
    • Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: A review
    • Crott R (2004) Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review. Pharmacoeconomics 22: 569-580
    • (2004) Pharmacoeconomics , vol.22 , pp. 569-580
    • Crott, R.1
  • 6
    • 3843097006 scopus 로고    scopus 로고
    • Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec
    • Crott R, Ali F, Burdette-Radoux S (2004) Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value Health 7: 423-432
    • (2004) Value Health , vol.7 , pp. 423-432
    • Crott, R.1    Ali, F.2    Burdette-Radoux, S.3
  • 7
    • 38349131636 scopus 로고    scopus 로고
    • Predicting utility ratings for joint health states from single health states in prostate cancer: Empirical testing of 3 alternative theories
    • Dale W, Basu A, Elstein A, Meltzer D (2002) Predicting utility ratings for joint health states from single health states in prostate cancer: empirical testing of 3 alternative theories. Med Decis Making 28: 102-112
    • (2002) Med Decis Making , vol.28 , pp. 102-112
    • Dale, W.1    Basu, A.2    Elstein, A.3    Meltzer, D.4
  • 8
    • 33344456866 scopus 로고    scopus 로고
    • Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: Results from randomised trial
    • Dixon S, Walters SJ, Turner L, Hancock BW (2006) Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 94: 492-498
    • (2006) Br J Cancer , vol.94 , pp. 492-498
    • Dixon, S.1    Walters, S.J.2    Turner, L.3    Hancock, B.W.4
  • 10
    • 68149148295 scopus 로고    scopus 로고
    • England and Wales Census, Data Table
    • England and Wales Census 2007 England and Wales Census, 2001 Data Table. http://www.statistics.gov.uk/census2001/table-list-cas.asp
    • (2007) England and Wales Census, 2001
  • 11
    • 33750981248 scopus 로고    scopus 로고
    • Deriving utility scores for co-morbid conditions: A test of the multiplicative model for combining individual condition scores
    • Flanagan W, McIntosh CN, Le PC, Berthelot JM (2006) Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores. Popul Health Metr 4: 13
    • (2006) Popul Health Metr , vol.4 , pp. 13
    • Flanagan, W.1    McIntosh2    CN, L.P.3    Berthelot, J.M.4
  • 12
    • 50949093888 scopus 로고    scopus 로고
    • Utilities should not be multiplied: Evidence from the preference-based scores in the United States
    • Fu AZ, Kattan MW (2008) Utilities should not be multiplied: evidence from the preference-based scores in the United States. Medical Care 46: 984-990
    • (2008) Medical Care , vol.46 , pp. 984-990
    • Fu, A.Z.1    Kattan, M.W.2
  • 13
    • 0346096833 scopus 로고    scopus 로고
    • Health-related quality of life in patients with advanced metastatic melanoma: Results of a randomized phase III study comparing temozolomide with dacarbazine
    • Kiebert GM, Jonas DL, Middleton MR (2003) Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 21: 821-829
    • (2003) Cancer Invest , vol.21 , pp. 821-829
    • Kiebert, G.M.1    Jonas, D.L.2    Middleton, M.R.3
  • 17
    • 4544286541 scopus 로고    scopus 로고
    • National Institute for Clinical Excellence NICE
    • National Institute for Clinical Excellence (NICE) (2004) Guide to the Methods of Technology Appraisal. p 20.
    • (2004) Guide to the Methods of Technology Appraisal , pp. 20
  • 18
    • 36849035139 scopus 로고    scopus 로고
    • NICE: London O'Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110: 2614-2627
    • NICE: London O'Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110: 2614-2627
  • 21
    • 22244440228 scopus 로고    scopus 로고
    • A national catalog of preference-based scores for chronic conditions in the United States
    • Sullivan PW, Lawrence WF, Ghushchyan V (2005) A national catalog of preference-based scores for chronic conditions in the United States. Med Care 43: 736-749
    • (2005) Med Care , vol.43 , pp. 736-749
    • Sullivan, P.W.1    Lawrence, W.F.2    Ghushchyan, V.3
  • 22
    • 0022633115 scopus 로고
    • Measurement of health state utilities for economic appraisal
    • Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5: 1-30
    • (1986) J Health Econ , vol.5 , pp. 1-30
    • Torrance, G.W.1
  • 23
    • 0003486933 scopus 로고
    • World Health Organization , WHO publication no. 48: Geneva, Switzerland
    • World Health Organization (1979) Handbook for Reporting Results of Cancer Treatment. WHO publication no. 48: Geneva, Switzerland
    • (1979) Handbook for Reporting Results of Cancer Treatment


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.